StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) stock

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.58−0.02 (-3.06%)

Close on Nov 20, 2026Market cap $55.36MP/E –Yield –

Cognition Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cognition Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$28.48M. For fiscal 2024 it was -$28.48M. The highest annual figure on record is -$3.44M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$28.48M–
FY2023Dec 31, 2023-$16.17M–
FY2022Dec 31, 2022-$18.70M–
FY2021Dec 31, 2021-$3.66M–
FY2020Dec 31, 2020-$3.44M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$8.38M–
Q3 FY2024Sep 30, 2024-$6.85M–
Q4 FY2023Dec 31, 2023-$5.49M–
Q3 FY2023Sep 30, 2023-$4.22M–
Q2 FY2023Jun 30, 2023-$3.71M–
Q1 FY2023Mar 31, 2023-$2.75M–
Q4 FY2022Dec 31, 2022-$10.19M–
Q3 FY2022Sep 30, 2022-$27.00K–
Q2 FY2022Jun 30, 2022-$5.36M–
Q1 FY2022Mar 31, 2022-$3.12M–
Q4 FY2020Dec 31, 2020-$480.00K–

More Cognition Therapeutics figures

See a number that looks wrong?